MétaCan
Menu
← Back to cohort

Adjuvant therapy in patients with resected pancreatic adenocarcinoma: Analysis of treatment allocation patterns in a Canadian provincial institution.

2021· article· en· W3125095552 on OpenAlexaffabout
Manik Chahal, Jonathan M. Loree, Howard J. Lim, Janine M. Davies, Daniel J. Renouf, Sharlene Gill

Bibliographic record

VenueJournal of Clinical Oncology · 2021
Typearticle
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsMedicineFOLFIRINOXGemcitabineRegimenInternal medicinePancreatic cancerCapecitabineStage (stratigraphy)OncologyLymphovascular invasionSurgeryOxaliplatinCancerMetastasis

Abstract

fetched live from OpenAlex

383 Background: In recent years adjuvant therapy (AT) for pancreatic cancer has evolved. Improved overall survival (OS) was demonstrated first in 2017 with gemcitabine and capecitabine (GemCap), and then further improved in 2018 with FOLFIRINOX compared to gemcitabine (gem) alone. Given these options, we retrospectively reviewed the patterns of AT allocation in the province of British Columbia (BC) during these periods of adoption of newer AT regimens. Methods: Patients (pts) treated at BC Cancer centers between January 2017 to June 2018 (the GemCap era), and July 2018 to July 2019 (the FOLFIRINOX era), who had undergone curative intent resection and received at least one cycle of AT were included for chart review. Patient and disease characteristics, treatment details, and stated rationale for choice of AT regimen were collected. Analyses were performed with one-way ANOVA for comparison of means between regimens, and Chi-squared or Fisher Exact tests to determine correlation between clinicopathologic factors and likelihood of undergoing a given AT regimen. Results: 122 pts were identified: 67 treated in the GemCap era (gem: 25, 37%, and GemCap: 42, 63%) and 55 treated in the FOLFIRINOX era (gem: 18, 33%, GemCap: 18, 33%, FOLFIRINOX: 19, 34%). Examined variables included age, gender, ECOG, T and N stage, margins, lymphovascular invasion and post-operative CA19-9. In the GemCap era, use of GemCap vs Gem was associated with younger average age (p = 0.001) and positive lymph node status (91% vs. 60%, p = 0.005). In the FOLFIRINOX era, use of gem AT was associated with a delayed time from surgery to consultation. (p = 0.036) AT assignment was not influenced by high volume vs low volume centre in the GemCap era; however, pts were more likely to receive GemCap in low-volume centres during the mFOLFIRINOX era (p = 0.045). The most common stated reasons for choice of a less intense AT regimen were pt comorbidities or functional status (GemCap era: 24% and FOLFIRINOX era: 31%). Conclusions: Despite improvements in survival with newer AT regimens, the majority of pts in our real-world setting were assigned a less intense AT regimen. Within the limits of a small sample size, significant pt or disease factors predictive of AT assignment were not identified aside from age and lymph node positivity in the GemCap era, and time from surgery to consultation in the FOLFIRINOX era. Efforts to improve adoption of newer AT regimens and optimize pt eligibility for FOLFIRINOX are warranted.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.067
Threshold uncertainty score0.136

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.005
Science and technology studies0.0020.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.091
GPT teacher head0.434
Teacher spread0.344 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicPancreatic and Hepatic Oncology Research→French-language works237,207→